Passage BIO, Inc.
PASG- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001787297
No open-market purchases or sales by Passage BIO, Inc. insiders were filed in the last 90 days; 29 institutions reported holding it in 13F filings for Q2 2026, worth $6.82M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Passage BIO, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 103 | 1 | 102 | 0 |
| Shares | 42.1M | 62.6K | 43.7M | +1.72M (+4.1%) |
| Value | $419.1M | $624.0K | $277.7M | −$140.8M (−33.6%) |
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held Passage BIO, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Deep Track Capital, LP | 3,216,997 | $20.4M | 1.51% |
| Great Point Partners LLC | 1,518,095 | $9.64M | 2.15% |
| Erste Asset Management GmbH | 535,000 | $3.34M | 0.06% |
| D. E. Shaw & Co., Inc. | 135,904 | $863.0K | 0.00% |
| Jacobs Levy Equity Management, Inc | 90,787 | $576.0K | 0.00% |
| Nomura Holdings Inc | 57,381 | $364.0K | 0.00% |
| Connor, Clark & Lunn Investment Management Ltd. | 23,313 | $148.0K | 0.00% |
| Parametric Portfolio Associates LLC | 21,108 | $134.0K | 0.00% |
| Walleye Capital LLC | 18,653 | $118.0K | 0.00% |
| Alpine Global Management, LLC | 14,570 | $93.0K | 0.01% |
| Ensign Peak Advisors, Inc | 13,270 | $84.0K | 0.00% |
| AQR Capital Management LLC | 11,641 | $74.0K | 0.00% |
| Denali Advisors LLC | 8,800 | $56.0K | 0.02% |
| Signaturefd, LLC | 395 | $3.00K | 0.00% |
| Lindbrook Capital, LLC | 500 | $3.00K | 0.00% |
| Federated Hermes, Inc. | 104 | $1.00K | 0.00% |
| Fortitude Advisory Group L.L.C. | 145 | $1.00K | 0.00% |
| Toronto Dominion Bank | 4 | $0 | 0.00% |
| CWM, LLC | 5 | $0 | 0.00% |
Sold out (19)
Institutions that held Passage BIO, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Boxer Capital, LLC | 1,928,315 | $19.2M |
| Vivo Capital, LLC | 539,263 | $5.37M |
| Emerald Advisers, LLC | 140,699 | $1.40M |
| Alyeska Investment Group, L.P. | 138,807 | $1.38M |
| Logos Global Management LP | 125,010 | $1.25M |
| Qube Research & Technologies Ltd | 23,113 | $230.0K |
| Dynamic Technology Lab Private Ltd | 17,771 | $177.0K |
| Virginia Retirement Systems Et Al | 15,900 | $158.0K |
| DekaBank Deutsche Girozentrale | 14,300 | $140.0K |
| UBS Asset Management Americas Inc | 11,470 | $114.2K |
| Jane Street Group, LLC | 11,399 | $114.0K |
| Pinz Capital Management, LP | 10,800 | $108.0K |
| Principal Financial Group Inc | 10,512 | $105.0K |
| Penserra Capital Management LLC | 1,235 | $12.0K |
| The PNC Financial Services Group, Inc. | 1,000 | $10.0K |
| Simplex Trading, LLC | 587 | $8.00K |
| Quadrant Capital Group LLC | 180 | $2.00K |
| Brewin Dolphin Ltd | 148 | $1.47K |
| Ellevest, Inc. | 8 | $0 |
Not filed for Q4 2021 yet (1)
Institutions that held Passage BIO, Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 62,586 | $624.0K |